dc.contributor.author | Rashtchizadeh, N | |
dc.contributor.author | Ghorbanihaghjo, A | |
dc.contributor.author | Argani, H | |
dc.contributor.author | Mahmoudi Meimand, S | |
dc.contributor.author | Safa, J | |
dc.contributor.author | Vatankhahan, H | |
dc.contributor.author | Shahidi, M | |
dc.date.accessioned | 2018-08-26T09:34:43Z | |
dc.date.available | 2018-08-26T09:34:43Z | |
dc.date.issued | 2012 | |
dc.identifier | 10.1111/j.1744-9987.2012.01097.x | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/57779 | |
dc.description.abstract | Serum receptor activator of nuclear factor-? B ligand and osteoprotegrin are mediated to vascular calcification in the general population. Our knowledge is very sparse in hemodialysis and renal transplant patients. Receptor activator of nuclear factor-? B ligand, osteoprotegrin, intact parathyroid hormone, calcium, and phosphorus were measured in blood samples of 45 hemodialysis and 45 age-matched renal transplant patients. Osteoprotegrin (P=0.001) and intact parathyroid hormone (P=0.001) levels in the hemodialysis patients were higher than the renal transplant recipients. Osteoprotegrin had positive correlation with duration of dialysis and age in the hemodialysis (r=0.88, P=0.001 and r=0.34, P=0.02, respectively) and renal transplant patients (r=0.92, P=0.001 and r=0.46, P=0.001, respectively). Hemodialysis patients have higher osteoprotegrin levels than the renal transplant recipients. It may act as a protective factor for renal osteodystrophy or only as a secondary phenomenon of advanced renal failure. © 2012 International Society for Apheresis. | |
dc.language.iso | English | |
dc.relation.ispartof | Therapeutic Apheresis and Dialysis | |
dc.subject | calcium | |
dc.subject | intact parathyroid hormone | |
dc.subject | osteoclast differentiation factor | |
dc.subject | osteoprotegrin | |
dc.subject | parathyroid hormone | |
dc.subject | phosphorus | |
dc.subject | protegrin | |
dc.subject | unclassified drug | |
dc.subject | adult | |
dc.subject | article | |
dc.subject | blood sampling | |
dc.subject | calcium blood level | |
dc.subject | female | |
dc.subject | graft recipient | |
dc.subject | hemodialysis patient | |
dc.subject | human | |
dc.subject | kidney transplantation | |
dc.subject | major clinical study | |
dc.subject | male | |
dc.subject | parathyroid hormone blood level | |
dc.subject | phosphate blood level | |
dc.subject | priority journal | |
dc.subject | protein blood level | |
dc.subject | Adult | |
dc.subject | Age Factors | |
dc.subject | Calcinosis | |
dc.subject | Calcium | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Kidney Transplantation | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Osteoprotegerin | |
dc.subject | Parathyroid Hormone | |
dc.subject | Phosphorus | |
dc.subject | RANK Ligand | |
dc.subject | Renal Dialysis | |
dc.subject | Renal Insufficiency | |
dc.subject | Time Factors | |
dc.title | Serum Receptor Activator of Nuclear Factor-? B Ligand, Osteoprotegrin, and Intact Parathyroid Hormone in Hemodialysis and Renal Transplant Patients | |
dc.type | Article | |
dc.citation.volume | 16 | |
dc.citation.issue | 6 | |
dc.citation.spage | 600 | |
dc.citation.epage | 604 | |
dc.citation.index | Scopus | |
dc.identifier.DOI | 10.1111/j.1744-9987.2012.01097.x | |